nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—Sulfaphenazole—Sulfasalazine—ankylosing spondylitis	0.261	1	CrCrCtD
Celecoxib—hematologic cancer—Methylprednisolone—ankylosing spondylitis	0.156	0.304	CpDpCtD
Celecoxib—colon cancer—Dexamethasone—ankylosing spondylitis	0.0702	0.137	CpDpCtD
Celecoxib—colon cancer—Betamethasone—ankylosing spondylitis	0.0702	0.137	CpDpCtD
Celecoxib—kidney cancer—Dexamethasone—ankylosing spondylitis	0.0508	0.0991	CpDpCtD
Celecoxib—kidney cancer—Betamethasone—ankylosing spondylitis	0.0508	0.0991	CpDpCtD
Celecoxib—prostate cancer—Dexamethasone—ankylosing spondylitis	0.0367	0.0716	CpDpCtD
Celecoxib—prostate cancer—Betamethasone—ankylosing spondylitis	0.0367	0.0716	CpDpCtD
Celecoxib—PTGS2—Triamcinolone—ankylosing spondylitis	0.0273	0.162	CbGbCtD
Celecoxib—PTGS2—Sulfasalazine—ankylosing spondylitis	0.0273	0.162	CbGbCtD
Celecoxib—PTGS2—Betamethasone—ankylosing spondylitis	0.0234	0.139	CbGbCtD
Celecoxib—osteoarthritis—Methylprednisolone—ankylosing spondylitis	0.0207	0.0403	CpDpCtD
Celecoxib—osteoarthritis—Prednisone—ankylosing spondylitis	0.0207	0.0403	CpDpCtD
Celecoxib—ABCC4—Methotrexate—ankylosing spondylitis	0.0186	0.111	CbGbCtD
Celecoxib—ALB—Prednisone—ankylosing spondylitis	0.0137	0.0817	CbGbCtD
Celecoxib—PTGS2—Dexamethasone—ankylosing spondylitis	0.0136	0.0808	CbGbCtD
Celecoxib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.00711	0.0422	CbGbCtD
Celecoxib—ALB—Methotrexate—ankylosing spondylitis	0.00689	0.041	CbGbCtD
Celecoxib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.00539	0.032	CbGbCtD
Celecoxib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.00462	0.0275	CbGbCtD
Celecoxib—CYP3A4—Betamethasone—ankylosing spondylitis	0.00462	0.0275	CbGbCtD
Celecoxib—CYP3A4—Prednisolone—ankylosing spondylitis	0.00456	0.0271	CbGbCtD
Celecoxib—CYP3A4—Prednisone—ankylosing spondylitis	0.00431	0.0256	CbGbCtD
Celecoxib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.00423	0.0251	CbGbCtD
Celecoxib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00269	0.016	CbGbCtD
Celecoxib—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000252	0.159	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000248	0.156	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000248	0.156	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000243	0.153	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.000152	0.0957	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.00015	0.0942	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.00015	0.0942	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000147	0.0921	CbGdCrCtD
Celecoxib—MAPK14—NOD1/2 Signaling Pathway—CARD9—ankylosing spondylitis	9.61e-05	0.0522	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	9.1e-05	0.0494	CbGpPWpGaD
Celecoxib—MAPK14—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CARD9—ankylosing spondylitis	6.56e-05	0.0356	CbGpPWpGaD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	5.82e-05	0.00105	CcSEcCtD
Celecoxib—Flushing—Prednisone—ankylosing spondylitis	5.81e-05	0.00105	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	5.78e-05	0.00105	CcSEcCtD
Celecoxib—Dry mouth—Triamcinolone—ankylosing spondylitis	5.74e-05	0.00104	CcSEcCtD
Celecoxib—Angioedema—Betamethasone—ankylosing spondylitis	5.72e-05	0.00104	CcSEcCtD
Celecoxib—Angioedema—Dexamethasone—ankylosing spondylitis	5.72e-05	0.00104	CcSEcCtD
Celecoxib—Stomatitis—Methotrexate—ankylosing spondylitis	5.68e-05	0.00103	CcSEcCtD
Celecoxib—Angiopathy—Prednisone—ankylosing spondylitis	5.68e-05	0.00103	CcSEcCtD
Celecoxib—Conjunctivitis—Methotrexate—ankylosing spondylitis	5.66e-05	0.00103	CcSEcCtD
Celecoxib—Confusional state—Methylprednisolone—ankylosing spondylitis	5.66e-05	0.00103	CcSEcCtD
Celecoxib—Immune system disorder—Prednisone—ankylosing spondylitis	5.65e-05	0.00102	CcSEcCtD
Celecoxib—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	5.63e-05	0.00102	CcSEcCtD
Celecoxib—Oedema—Triamcinolone—ankylosing spondylitis	5.63e-05	0.00102	CcSEcCtD
Celecoxib—Vertigo—Betamethasone—ankylosing spondylitis	5.62e-05	0.00102	CcSEcCtD
Celecoxib—Vertigo—Dexamethasone—ankylosing spondylitis	5.62e-05	0.00102	CcSEcCtD
Celecoxib—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	5.62e-05	0.00102	CcSEcCtD
Celecoxib—Syncope—Betamethasone—ankylosing spondylitis	5.61e-05	0.00102	CcSEcCtD
Celecoxib—Syncope—Dexamethasone—ankylosing spondylitis	5.61e-05	0.00102	CcSEcCtD
Celecoxib—Arrhythmia—Prednisone—ankylosing spondylitis	5.59e-05	0.00101	CcSEcCtD
Celecoxib—Infection—Triamcinolone—ankylosing spondylitis	5.59e-05	0.00101	CcSEcCtD
Celecoxib—Infection—Methylprednisolone—ankylosing spondylitis	5.58e-05	0.00101	CcSEcCtD
Celecoxib—Haematuria—Methotrexate—ankylosing spondylitis	5.56e-05	0.00101	CcSEcCtD
Celecoxib—Shock—Triamcinolone—ankylosing spondylitis	5.54e-05	0.001	CcSEcCtD
Celecoxib—Insomnia—Prednisolone—ankylosing spondylitis	5.54e-05	0.001	CcSEcCtD
Celecoxib—Alopecia—Prednisone—ankylosing spondylitis	5.53e-05	0.001	CcSEcCtD
Celecoxib—Shock—Methylprednisolone—ankylosing spondylitis	5.53e-05	0.001	CcSEcCtD
Celecoxib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	5.51e-05	0.000998	CcSEcCtD
Celecoxib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	5.51e-05	0.000997	CcSEcCtD
Celecoxib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	5.5e-05	0.000996	CcSEcCtD
Celecoxib—Loss of consciousness—Betamethasone—ankylosing spondylitis	5.5e-05	0.000996	CcSEcCtD
Celecoxib—Epistaxis—Methotrexate—ankylosing spondylitis	5.5e-05	0.000995	CcSEcCtD
Celecoxib—Paraesthesia—Prednisolone—ankylosing spondylitis	5.5e-05	0.000995	CcSEcCtD
Celecoxib—Tachycardia—Triamcinolone—ankylosing spondylitis	5.49e-05	0.000994	CcSEcCtD
Celecoxib—Mental disorder—Prednisone—ankylosing spondylitis	5.48e-05	0.000993	CcSEcCtD
Celecoxib—Tachycardia—Methylprednisolone—ankylosing spondylitis	5.48e-05	0.000992	CcSEcCtD
Celecoxib—Skin disorder—Methylprednisolone—ankylosing spondylitis	5.45e-05	0.000988	CcSEcCtD
Celecoxib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	5.44e-05	0.000985	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—ankylosing spondylitis	5.44e-05	0.000985	CcSEcCtD
Celecoxib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	5.43e-05	0.000983	CcSEcCtD
Celecoxib—Hypertension—Dexamethasone—ankylosing spondylitis	5.4e-05	0.000978	CcSEcCtD
Celecoxib—Hypertension—Betamethasone—ankylosing spondylitis	5.4e-05	0.000978	CcSEcCtD
Celecoxib—Myalgia—Betamethasone—ankylosing spondylitis	5.33e-05	0.000964	CcSEcCtD
Celecoxib—Myalgia—Dexamethasone—ankylosing spondylitis	5.33e-05	0.000964	CcSEcCtD
Celecoxib—Anxiety—Dexamethasone—ankylosing spondylitis	5.31e-05	0.000961	CcSEcCtD
Celecoxib—Anxiety—Betamethasone—ankylosing spondylitis	5.31e-05	0.000961	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—ankylosing spondylitis	5.26e-05	0.000952	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—ankylosing spondylitis	5.23e-05	0.000947	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—ankylosing spondylitis	5.23e-05	0.000947	CcSEcCtD
Celecoxib—Pharyngitis—Methotrexate—ankylosing spondylitis	5.19e-05	0.00094	CcSEcCtD
Celecoxib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	5.17e-05	0.000935	CcSEcCtD
Celecoxib—Vision blurred—Prednisone—ankylosing spondylitis	5.14e-05	0.00093	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—ankylosing spondylitis	5.13e-05	0.000928	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	5.13e-05	0.000928	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	5.12e-05	0.000926	CcSEcCtD
Celecoxib—Oedema—Dexamethasone—ankylosing spondylitis	5.11e-05	0.000925	CcSEcCtD
Celecoxib—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	5.11e-05	0.000925	CcSEcCtD
Celecoxib—Oedema—Betamethasone—ankylosing spondylitis	5.11e-05	0.000925	CcSEcCtD
Celecoxib—Anaphylactic shock—Betamethasone—ankylosing spondylitis	5.11e-05	0.000925	CcSEcCtD
Celecoxib—Insomnia—Triamcinolone—ankylosing spondylitis	5.09e-05	0.000922	CcSEcCtD
Celecoxib—Insomnia—Methylprednisolone—ankylosing spondylitis	5.08e-05	0.00092	CcSEcCtD
Celecoxib—Infection—Dexamethasone—ankylosing spondylitis	5.07e-05	0.000919	CcSEcCtD
Celecoxib—Infection—Betamethasone—ankylosing spondylitis	5.07e-05	0.000919	CcSEcCtD
Celecoxib—Paraesthesia—Triamcinolone—ankylosing spondylitis	5.05e-05	0.000915	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisolone—ankylosing spondylitis	5.04e-05	0.000913	CcSEcCtD
Celecoxib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	5.04e-05	0.000913	CcSEcCtD
Celecoxib—Anaemia—Prednisone—ankylosing spondylitis	5.04e-05	0.000912	CcSEcCtD
Celecoxib—Shock—Dexamethasone—ankylosing spondylitis	5.02e-05	0.00091	CcSEcCtD
Celecoxib—Shock—Betamethasone—ankylosing spondylitis	5.02e-05	0.00091	CcSEcCtD
Celecoxib—Dyspnoea—Triamcinolone—ankylosing spondylitis	5.02e-05	0.000908	CcSEcCtD
Celecoxib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	5.01e-05	0.000907	CcSEcCtD
Celecoxib—Nervous system disorder—Betamethasone—ankylosing spondylitis	5.01e-05	0.000907	CcSEcCtD
Celecoxib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	5e-05	0.000905	CcSEcCtD
Celecoxib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	5e-05	0.000905	CcSEcCtD
Celecoxib—Tachycardia—Betamethasone—ankylosing spondylitis	4.98e-05	0.000902	CcSEcCtD
Celecoxib—Tachycardia—Dexamethasone—ankylosing spondylitis	4.98e-05	0.000902	CcSEcCtD
Celecoxib—Angioedema—Prednisone—ankylosing spondylitis	4.98e-05	0.000901	CcSEcCtD
Celecoxib—Dyspepsia—Triamcinolone—ankylosing spondylitis	4.95e-05	0.000897	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—ankylosing spondylitis	4.95e-05	0.000896	CcSEcCtD
Celecoxib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	4.94e-05	0.000895	CcSEcCtD
Celecoxib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	4.94e-05	0.000894	CcSEcCtD
Celecoxib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	4.94e-05	0.000894	CcSEcCtD
Celecoxib—Vertigo—Prednisone—ankylosing spondylitis	4.9e-05	0.000886	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—ankylosing spondylitis	4.89e-05	0.000885	CcSEcCtD
Celecoxib—Syncope—Prednisone—ankylosing spondylitis	4.89e-05	0.000885	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—ankylosing spondylitis	4.88e-05	0.000883	CcSEcCtD
Celecoxib—Anorexia—Betamethasone—ankylosing spondylitis	4.87e-05	0.000881	CcSEcCtD
Celecoxib—Anorexia—Dexamethasone—ankylosing spondylitis	4.87e-05	0.000881	CcSEcCtD
Celecoxib—Urticaria—Prednisolone—ankylosing spondylitis	4.86e-05	0.00088	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—ankylosing spondylitis	4.86e-05	0.000879	CcSEcCtD
Celecoxib—Fatigue—Triamcinolone—ankylosing spondylitis	4.85e-05	0.000879	CcSEcCtD
Celecoxib—Fatigue—Methylprednisolone—ankylosing spondylitis	4.84e-05	0.000877	CcSEcCtD
Celecoxib—Loss of consciousness—Prednisone—ankylosing spondylitis	4.79e-05	0.000867	CcSEcCtD
Celecoxib—PDPK1—BCR signaling pathway—CD79A—ankylosing spondylitis	4.78e-05	0.026	CbGpPWpGaD
Celecoxib—Angiopathy—Methotrexate—ankylosing spondylitis	4.75e-05	0.000859	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—ankylosing spondylitis	4.73e-05	0.000856	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	4.72e-05	0.000854	CcSEcCtD
Celecoxib—Hypertension—Prednisone—ankylosing spondylitis	4.7e-05	0.000852	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	4.65e-05	0.000842	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	4.65e-05	0.000842	CcSEcCtD
Celecoxib—Arthralgia—Prednisone—ankylosing spondylitis	4.64e-05	0.00084	CcSEcCtD
Celecoxib—Myalgia—Prednisone—ankylosing spondylitis	4.64e-05	0.00084	CcSEcCtD
Celecoxib—Feeling abnormal—Triamcinolone—ankylosing spondylitis	4.64e-05	0.00084	CcSEcCtD
Celecoxib—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	4.63e-05	0.000838	CcSEcCtD
Celecoxib—Anxiety—Prednisone—ankylosing spondylitis	4.62e-05	0.000837	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—ankylosing spondylitis	4.62e-05	0.000837	CcSEcCtD
Celecoxib—Insomnia—Dexamethasone—ankylosing spondylitis	4.62e-05	0.000836	CcSEcCtD
Celecoxib—Insomnia—Betamethasone—ankylosing spondylitis	4.62e-05	0.000836	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	4.61e-05	0.000834	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	4.59e-05	0.000831	CcSEcCtD
Celecoxib—Paraesthesia—Dexamethasone—ankylosing spondylitis	4.59e-05	0.00083	CcSEcCtD
Celecoxib—Paraesthesia—Betamethasone—ankylosing spondylitis	4.59e-05	0.00083	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—ankylosing spondylitis	4.58e-05	0.00083	CcSEcCtD
Celecoxib—PDPK1—TCR Signaling Pathway—IL17A—ankylosing spondylitis	4.53e-05	0.0246	CbGpPWpGaD
Celecoxib—Hypersensitivity—Prednisolone—ankylosing spondylitis	4.51e-05	0.000816	CcSEcCtD
Celecoxib—Dyspepsia—Dexamethasone—ankylosing spondylitis	4.5e-05	0.000814	CcSEcCtD
Celecoxib—Dyspepsia—Betamethasone—ankylosing spondylitis	4.5e-05	0.000814	CcSEcCtD
Celecoxib—Urticaria—Triamcinolone—ankylosing spondylitis	4.47e-05	0.000809	CcSEcCtD
Celecoxib—Urticaria—Methylprednisolone—ankylosing spondylitis	4.46e-05	0.000808	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—ankylosing spondylitis	4.46e-05	0.000807	CcSEcCtD
Celecoxib—Body temperature increased—Triamcinolone—ankylosing spondylitis	4.45e-05	0.000806	CcSEcCtD
Celecoxib—Oedema—Prednisone—ankylosing spondylitis	4.45e-05	0.000805	CcSEcCtD
Celecoxib—Anaphylactic shock—Prednisone—ankylosing spondylitis	4.45e-05	0.000805	CcSEcCtD
Celecoxib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	4.44e-05	0.000804	CcSEcCtD
Celecoxib—Decreased appetite—Dexamethasone—ankylosing spondylitis	4.44e-05	0.000804	CcSEcCtD
Celecoxib—Decreased appetite—Betamethasone—ankylosing spondylitis	4.44e-05	0.000804	CcSEcCtD
Celecoxib—Infection—Prednisone—ankylosing spondylitis	4.42e-05	0.0008	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	4.41e-05	0.000798	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	4.41e-05	0.000798	CcSEcCtD
Celecoxib—Back pain—Methotrexate—ankylosing spondylitis	4.41e-05	0.000798	CcSEcCtD
Celecoxib—Fatigue—Dexamethasone—ankylosing spondylitis	4.4e-05	0.000797	CcSEcCtD
Celecoxib—Fatigue—Betamethasone—ankylosing spondylitis	4.4e-05	0.000797	CcSEcCtD
Celecoxib—Shock—Prednisone—ankylosing spondylitis	4.38e-05	0.000792	CcSEcCtD
Celecoxib—Nervous system disorder—Prednisone—ankylosing spondylitis	4.36e-05	0.00079	CcSEcCtD
Celecoxib—Tachycardia—Prednisone—ankylosing spondylitis	4.34e-05	0.000786	CcSEcCtD
Celecoxib—Skin disorder—Prednisone—ankylosing spondylitis	4.32e-05	0.000782	CcSEcCtD
Celecoxib—Hyperhidrosis—Prednisone—ankylosing spondylitis	4.3e-05	0.000778	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—ankylosing spondylitis	4.29e-05	0.000777	CcSEcCtD
Celecoxib—Anorexia—Prednisone—ankylosing spondylitis	4.24e-05	0.000767	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—ankylosing spondylitis	4.21e-05	0.000762	CcSEcCtD
Celecoxib—Feeling abnormal—Betamethasone—ankylosing spondylitis	4.21e-05	0.000762	CcSEcCtD
Celecoxib—Feeling abnormal—Dexamethasone—ankylosing spondylitis	4.21e-05	0.000762	CcSEcCtD
Celecoxib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	4.18e-05	0.000756	CcSEcCtD
Celecoxib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	4.18e-05	0.000756	CcSEcCtD
Celecoxib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	4.15e-05	0.000751	CcSEcCtD
Celecoxib—PDPK1—TCR signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	4.14e-05	0.0225	CbGpPWpGaD
Celecoxib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	4.14e-05	0.000749	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—ankylosing spondylitis	4.09e-05	0.000741	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—ankylosing spondylitis	4.08e-05	0.000738	CcSEcCtD
Celecoxib—Urticaria—Betamethasone—ankylosing spondylitis	4.06e-05	0.000734	CcSEcCtD
Celecoxib—Urticaria—Dexamethasone—ankylosing spondylitis	4.06e-05	0.000734	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	4.05e-05	0.000734	CcSEcCtD
Celecoxib—Dizziness—Prednisolone—ankylosing spondylitis	4.05e-05	0.000733	CcSEcCtD
Celecoxib—Asthenia—Triamcinolone—ankylosing spondylitis	4.04e-05	0.000731	CcSEcCtD
Celecoxib—Body temperature increased—Betamethasone—ankylosing spondylitis	4.04e-05	0.000731	CcSEcCtD
Celecoxib—Body temperature increased—Dexamethasone—ankylosing spondylitis	4.04e-05	0.000731	CcSEcCtD
Celecoxib—Abdominal pain—Dexamethasone—ankylosing spondylitis	4.04e-05	0.000731	CcSEcCtD
Celecoxib—Abdominal pain—Betamethasone—ankylosing spondylitis	4.04e-05	0.000731	CcSEcCtD
Celecoxib—Asthenia—Methylprednisolone—ankylosing spondylitis	4.03e-05	0.000729	CcSEcCtD
Celecoxib—Insomnia—Prednisone—ankylosing spondylitis	4.02e-05	0.000728	CcSEcCtD
Celecoxib—Paraesthesia—Prednisone—ankylosing spondylitis	3.99e-05	0.000723	CcSEcCtD
Celecoxib—Pruritus—Triamcinolone—ankylosing spondylitis	3.98e-05	0.000721	CcSEcCtD
Celecoxib—Cough—Methotrexate—ankylosing spondylitis	3.97e-05	0.000719	CcSEcCtD
Celecoxib—Pruritus—Methylprednisolone—ankylosing spondylitis	3.97e-05	0.000719	CcSEcCtD
Celecoxib—Dyspepsia—Prednisone—ankylosing spondylitis	3.91e-05	0.000709	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—ankylosing spondylitis	3.88e-05	0.000702	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—ankylosing spondylitis	3.88e-05	0.000702	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—ankylosing spondylitis	3.88e-05	0.000702	CcSEcCtD
Celecoxib—Decreased appetite—Prednisone—ankylosing spondylitis	3.87e-05	0.0007	CcSEcCtD
Celecoxib—Rash—Prednisolone—ankylosing spondylitis	3.86e-05	0.000699	CcSEcCtD
Celecoxib—Dermatitis—Prednisolone—ankylosing spondylitis	3.86e-05	0.000698	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	3.85e-05	0.000697	CcSEcCtD
Celecoxib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	3.84e-05	0.000696	CcSEcCtD
Celecoxib—Fatigue—Prednisone—ankylosing spondylitis	3.83e-05	0.000694	CcSEcCtD
Celecoxib—Headache—Prednisolone—ankylosing spondylitis	3.83e-05	0.000694	CcSEcCtD
Celecoxib—Constipation—Prednisone—ankylosing spondylitis	3.8e-05	0.000689	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—ankylosing spondylitis	3.75e-05	0.000678	CcSEcCtD
Celecoxib—Dizziness—Triamcinolone—ankylosing spondylitis	3.72e-05	0.000674	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—ankylosing spondylitis	3.72e-05	0.000673	CcSEcCtD
Celecoxib—Dizziness—Methylprednisolone—ankylosing spondylitis	3.71e-05	0.000672	CcSEcCtD
Celecoxib—Infection—Methotrexate—ankylosing spondylitis	3.69e-05	0.000669	CcSEcCtD
Celecoxib—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	3.68e-05	0.02	CbGpPWpGaD
Celecoxib—Feeling abnormal—Prednisone—ankylosing spondylitis	3.67e-05	0.000664	CcSEcCtD
Celecoxib—Asthenia—Dexamethasone—ankylosing spondylitis	3.66e-05	0.000663	CcSEcCtD
Celecoxib—Asthenia—Betamethasone—ankylosing spondylitis	3.66e-05	0.000663	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—ankylosing spondylitis	3.65e-05	0.00066	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	3.64e-05	0.000659	CcSEcCtD
Celecoxib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	3.64e-05	0.000658	CcSEcCtD
Celecoxib—Nausea—Prednisolone—ankylosing spondylitis	3.64e-05	0.000658	CcSEcCtD
Celecoxib—Pruritus—Dexamethasone—ankylosing spondylitis	3.61e-05	0.000654	CcSEcCtD
Celecoxib—Pruritus—Betamethasone—ankylosing spondylitis	3.61e-05	0.000654	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—ankylosing spondylitis	3.61e-05	0.000654	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	3.59e-05	0.000651	CcSEcCtD
Celecoxib—Vomiting—Triamcinolone—ankylosing spondylitis	3.58e-05	0.000648	CcSEcCtD
Celecoxib—Vomiting—Methylprednisolone—ankylosing spondylitis	3.57e-05	0.000646	CcSEcCtD
Celecoxib—PDPK1—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	3.56e-05	0.0193	CbGpPWpGaD
Celecoxib—Rash—Triamcinolone—ankylosing spondylitis	3.55e-05	0.000642	CcSEcCtD
Celecoxib—Dermatitis—Triamcinolone—ankylosing spondylitis	3.55e-05	0.000642	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—ankylosing spondylitis	3.54e-05	0.000641	CcSEcCtD
Celecoxib—Rash—Methylprednisolone—ankylosing spondylitis	3.54e-05	0.000641	CcSEcCtD
Celecoxib—Dermatitis—Methylprednisolone—ankylosing spondylitis	3.54e-05	0.00064	CcSEcCtD
Celecoxib—Urticaria—Prednisone—ankylosing spondylitis	3.53e-05	0.00064	CcSEcCtD
Celecoxib—Headache—Triamcinolone—ankylosing spondylitis	3.53e-05	0.000638	CcSEcCtD
Celecoxib—Headache—Methylprednisolone—ankylosing spondylitis	3.52e-05	0.000637	CcSEcCtD
Celecoxib—Abdominal pain—Prednisone—ankylosing spondylitis	3.52e-05	0.000637	CcSEcCtD
Celecoxib—Body temperature increased—Prednisone—ankylosing spondylitis	3.52e-05	0.000637	CcSEcCtD
Celecoxib—Diarrhoea—Dexamethasone—ankylosing spondylitis	3.49e-05	0.000633	CcSEcCtD
Celecoxib—Diarrhoea—Betamethasone—ankylosing spondylitis	3.49e-05	0.000633	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	3.39e-05	0.000613	CcSEcCtD
Celecoxib—Dizziness—Betamethasone—ankylosing spondylitis	3.38e-05	0.000611	CcSEcCtD
Celecoxib—Dizziness—Dexamethasone—ankylosing spondylitis	3.38e-05	0.000611	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—ankylosing spondylitis	3.36e-05	0.000609	CcSEcCtD
Celecoxib—Nausea—Triamcinolone—ankylosing spondylitis	3.34e-05	0.000605	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—ankylosing spondylitis	3.34e-05	0.000604	CcSEcCtD
Celecoxib—Nausea—Methylprednisolone—ankylosing spondylitis	3.34e-05	0.000604	CcSEcCtD
Celecoxib—MAPK14—CD40/CD40L signaling—CD40LG—ankylosing spondylitis	3.33e-05	0.0181	CbGpPWpGaD
Celecoxib—Dyspnoea—Methotrexate—ankylosing spondylitis	3.31e-05	0.0006	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—ankylosing spondylitis	3.3e-05	0.000598	CcSEcCtD
Celecoxib—Hypersensitivity—Prednisone—ankylosing spondylitis	3.28e-05	0.000593	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—ankylosing spondylitis	3.27e-05	0.000592	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	3.26e-05	0.0177	CbGpPWpGaD
Celecoxib—Vomiting—Dexamethasone—ankylosing spondylitis	3.25e-05	0.000588	CcSEcCtD
Celecoxib—Vomiting—Betamethasone—ankylosing spondylitis	3.25e-05	0.000588	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—ankylosing spondylitis	3.23e-05	0.000585	CcSEcCtD
Celecoxib—Rash—Dexamethasone—ankylosing spondylitis	3.22e-05	0.000583	CcSEcCtD
Celecoxib—Rash—Betamethasone—ankylosing spondylitis	3.22e-05	0.000583	CcSEcCtD
Celecoxib—Dermatitis—Betamethasone—ankylosing spondylitis	3.22e-05	0.000582	CcSEcCtD
Celecoxib—Dermatitis—Dexamethasone—ankylosing spondylitis	3.22e-05	0.000582	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	3.21e-05	0.000581	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—ankylosing spondylitis	3.2e-05	0.00058	CcSEcCtD
Celecoxib—Headache—Dexamethasone—ankylosing spondylitis	3.2e-05	0.000579	CcSEcCtD
Celecoxib—Headache—Betamethasone—ankylosing spondylitis	3.2e-05	0.000579	CcSEcCtD
Celecoxib—Asthenia—Prednisone—ankylosing spondylitis	3.19e-05	0.000578	CcSEcCtD
Celecoxib—Pruritus—Prednisone—ankylosing spondylitis	3.15e-05	0.00057	CcSEcCtD
Celecoxib—PDPK1—TCR Signaling Pathway—IL1A—ankylosing spondylitis	3.1e-05	0.0168	CbGpPWpGaD
Celecoxib—Feeling abnormal—Methotrexate—ankylosing spondylitis	3.06e-05	0.000555	CcSEcCtD
Celecoxib—Diarrhoea—Prednisone—ankylosing spondylitis	3.04e-05	0.000551	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	3.04e-05	0.00055	CcSEcCtD
Celecoxib—Nausea—Betamethasone—ankylosing spondylitis	3.03e-05	0.000549	CcSEcCtD
Celecoxib—Nausea—Dexamethasone—ankylosing spondylitis	3.03e-05	0.000549	CcSEcCtD
Celecoxib—MAPK14—IL12-mediated signaling events—IL12B—ankylosing spondylitis	3.03e-05	0.0164	CbGpPWpGaD
Celecoxib—PTGS2—Overview of nanoparticle effects—CRP—ankylosing spondylitis	2.98e-05	0.0162	CbGpPWpGaD
Celecoxib—Urticaria—Methotrexate—ankylosing spondylitis	2.95e-05	0.000535	CcSEcCtD
Celecoxib—Dizziness—Prednisone—ankylosing spondylitis	2.94e-05	0.000532	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—ankylosing spondylitis	2.94e-05	0.000532	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—ankylosing spondylitis	2.94e-05	0.000532	CcSEcCtD
Celecoxib—PDPK1—DAP12 interactions—HLA-C—ankylosing spondylitis	2.88e-05	0.0156	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	2.87e-05	0.0156	CbGpPWpGaD
Celecoxib—Vomiting—Prednisone—ankylosing spondylitis	2.83e-05	0.000512	CcSEcCtD
Celecoxib—Rash—Prednisone—ankylosing spondylitis	2.8e-05	0.000508	CcSEcCtD
Celecoxib—Dermatitis—Prednisone—ankylosing spondylitis	2.8e-05	0.000507	CcSEcCtD
Celecoxib—Headache—Prednisone—ankylosing spondylitis	2.79e-05	0.000504	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—ankylosing spondylitis	2.74e-05	0.000496	CcSEcCtD
Celecoxib—MAPK14—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	2.71e-05	0.0147	CbGpPWpGaD
Celecoxib—Asthenia—Methotrexate—ankylosing spondylitis	2.67e-05	0.000483	CcSEcCtD
Celecoxib—Nausea—Prednisone—ankylosing spondylitis	2.64e-05	0.000478	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—ankylosing spondylitis	2.63e-05	0.000476	CcSEcCtD
Celecoxib—MAPK14—Leptin signaling pathway—IL1RN—ankylosing spondylitis	2.59e-05	0.014	CbGpPWpGaD
Celecoxib—Diarrhoea—Methotrexate—ankylosing spondylitis	2.54e-05	0.00046	CcSEcCtD
Celecoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	2.53e-05	0.0137	CbGpPWpGaD
Celecoxib—MAPK14—BCR signaling pathway—CD79A—ankylosing spondylitis	2.48e-05	0.0135	CbGpPWpGaD
Celecoxib—Dizziness—Methotrexate—ankylosing spondylitis	2.46e-05	0.000445	CcSEcCtD
Celecoxib—MAPK14—IL-1 signaling pathway—IL1A—ankylosing spondylitis	2.39e-05	0.0129	CbGpPWpGaD
Celecoxib—Vomiting—Methotrexate—ankylosing spondylitis	2.36e-05	0.000428	CcSEcCtD
Celecoxib—MAPK14—TCR Signaling Pathway—IL17A—ankylosing spondylitis	2.35e-05	0.0128	CbGpPWpGaD
Celecoxib—Rash—Methotrexate—ankylosing spondylitis	2.34e-05	0.000424	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—ankylosing spondylitis	2.34e-05	0.000424	CcSEcCtD
Celecoxib—Headache—Methotrexate—ankylosing spondylitis	2.33e-05	0.000422	CcSEcCtD
Celecoxib—MAPK14—IL6-mediated signaling events—CRP—ankylosing spondylitis	2.26e-05	0.0123	CbGpPWpGaD
Celecoxib—Nausea—Methotrexate—ankylosing spondylitis	2.21e-05	0.0004	CcSEcCtD
Celecoxib—MAPK14—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	2.21e-05	0.012	CbGpPWpGaD
Celecoxib—MAPK14—IL4-mediated signaling events—CD40LG—ankylosing spondylitis	2.16e-05	0.0117	CbGpPWpGaD
Celecoxib—MAPK14—IL4-mediated signaling events—IL10—ankylosing spondylitis	2.16e-05	0.0117	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—CD79A—ankylosing spondylitis	2.03e-05	0.011	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	1.98e-05	0.0107	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KIR3DL1—ankylosing spondylitis	1.98e-05	0.0107	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	1.95e-05	0.0106	CbGpPWpGaD
Celecoxib—ABCC4—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	1.94e-05	0.0105	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—ERAP1—ankylosing spondylitis	1.87e-05	0.0102	CbGpPWpGaD
Celecoxib—MAPK14—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	1.85e-05	0.01	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CARD9—ankylosing spondylitis	1.78e-05	0.00968	CbGpPWpGaD
Celecoxib—PDPK1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	1.74e-05	0.00943	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—HLA-B—ankylosing spondylitis	1.7e-05	0.00925	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	1.64e-05	0.00888	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—IL1A—ankylosing spondylitis	1.61e-05	0.00873	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	1.55e-05	0.00839	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	1.42e-05	0.00772	CbGpPWpGaD
Celecoxib—MAPK14—Monoamine Transport—TNF—ankylosing spondylitis	1.39e-05	0.00756	CbGpPWpGaD
Celecoxib—PDPK1—Disease—ANTXR2—ankylosing spondylitis	1.38e-05	0.00751	CbGpPWpGaD
Celecoxib—PTGS2—Overview of nanoparticle effects—TNF—ankylosing spondylitis	1.35e-05	0.00733	CbGpPWpGaD
Celecoxib—MAPK14—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	1.27e-05	0.00688	CbGpPWpGaD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	1.25e-05	0.00676	CbGpPWpGaD
Celecoxib—PDPK1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	1.24e-05	0.00672	CbGpPWpGaD
Celecoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—ankylosing spondylitis	1.21e-05	0.00659	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL1R2—ankylosing spondylitis	1.2e-05	0.0065	CbGpPWpGaD
Celecoxib—MAPK14—MyD88-independent cascade—TLR4—ankylosing spondylitis	1.19e-05	0.00649	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	1.17e-05	0.00633	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—ERAP1—ankylosing spondylitis	1.14e-05	0.00616	CbGpPWpGaD
Celecoxib—CA9—Cellular responses to stress—IL1A—ankylosing spondylitis	1.13e-05	0.00612	CbGpPWpGaD
Celecoxib—MAPK14—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	1.12e-05	0.00608	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—HLA-C—ankylosing spondylitis	1.12e-05	0.00608	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	1.09e-05	0.00594	CbGpPWpGaD
Celecoxib—CA14—Metabolism—B3GNT2—ankylosing spondylitis	1.08e-05	0.00588	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HLA-C—ankylosing spondylitis	1.08e-05	0.00584	CbGpPWpGaD
Celecoxib—MAPK14—Activated TLR4 signalling—TLR4—ankylosing spondylitis	1.07e-05	0.00583	CbGpPWpGaD
Celecoxib—CA6—Metabolism—B3GNT2—ankylosing spondylitis	1.06e-05	0.00573	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—B3GNT2—ankylosing spondylitis	1.06e-05	0.00573	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CARD9—ankylosing spondylitis	1.04e-05	0.00564	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KIR3DL1—ankylosing spondylitis	1.03e-05	0.00558	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	1.01e-05	0.00549	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—B3GNT2—ankylosing spondylitis	9.85e-06	0.00535	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	9.77e-06	0.0053	CbGpPWpGaD
Celecoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—ankylosing spondylitis	9.74e-06	0.00529	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CARD9—ankylosing spondylitis	9.27e-06	0.00503	CbGpPWpGaD
Celecoxib—CA12—Metabolism—B3GNT2—ankylosing spondylitis	9.13e-06	0.00495	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	9.11e-06	0.00494	CbGpPWpGaD
Celecoxib—MAPK14—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	9.03e-06	0.0049	CbGpPWpGaD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	9e-06	0.00489	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—IL1A—ankylosing spondylitis	9e-06	0.00489	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—CRP—ankylosing spondylitis	8.91e-06	0.00484	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	8.77e-06	0.00476	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—CRP—ankylosing spondylitis	8.75e-06	0.00475	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL1A—ankylosing spondylitis	8.28e-06	0.00449	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD79A—ankylosing spondylitis	8.2e-06	0.00445	CbGpPWpGaD
Celecoxib—PDPK1—Disease—B3GNT2—ankylosing spondylitis	8.15e-06	0.00443	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	7.3e-06	0.00396	CbGpPWpGaD
Celecoxib—CA4—Metabolism—B3GNT2—ankylosing spondylitis	7.28e-06	0.00395	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	7.08e-06	0.00384	CbGpPWpGaD
Celecoxib—CA2—Metabolism—B3GNT2—ankylosing spondylitis	6.98e-06	0.00379	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—IL1A—ankylosing spondylitis	6.8e-06	0.00369	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.69e-06	0.00363	CbGpPWpGaD
Celecoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	6.65e-06	0.00361	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TLR4—ankylosing spondylitis	6.63e-06	0.0036	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.63e-06	0.0036	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—HLA-B—ankylosing spondylitis	6.62e-06	0.00359	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-C—ankylosing spondylitis	6.52e-06	0.00354	CbGpPWpGaD
Celecoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	6.43e-06	0.00349	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.36e-06	0.00345	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL1R2—ankylosing spondylitis	6.23e-06	0.00338	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	6.22e-06	0.00338	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ERAP1—ankylosing spondylitis	5.9e-06	0.0032	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HLA-A—ankylosing spondylitis	5.89e-06	0.0032	CbGpPWpGaD
Celecoxib—CA9—Metabolism—B3GNT2—ankylosing spondylitis	5.88e-06	0.00319	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CRP—ankylosing spondylitis	5.85e-06	0.00318	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HLA-C—ankylosing spondylitis	5.82e-06	0.00316	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL1RN—ankylosing spondylitis	5.67e-06	0.00308	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—TLR4—ankylosing spondylitis	5.61e-06	0.00305	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	5.51e-06	0.00299	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CARD9—ankylosing spondylitis	5.4e-06	0.00293	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD79A—ankylosing spondylitis	4.97e-06	0.0027	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	4.96e-06	0.00269	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—MMP3—ankylosing spondylitis	4.72e-06	0.00256	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ANTXR2—ankylosing spondylitis	4.59e-06	0.00249	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	4.3e-06	0.00233	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL1A—ankylosing spondylitis	4.08e-06	0.00221	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD40LG—ankylosing spondylitis	4.06e-06	0.0022	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—TNF—ankylosing spondylitis	4.03e-06	0.00219	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—TNF—ankylosing spondylitis	3.96e-06	0.00215	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTGER4—ankylosing spondylitis	3.92e-06	0.00213	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-B—ankylosing spondylitis	3.86e-06	0.00209	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—TNF—ankylosing spondylitis	3.7e-06	0.00201	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-A—ankylosing spondylitis	3.57e-06	0.00194	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HLA-B—ankylosing spondylitis	3.44e-06	0.00187	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CRP—ankylosing spondylitis	3.41e-06	0.00185	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-C—ankylosing spondylitis	3.39e-06	0.00184	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.33e-06	0.00181	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HLA-A—ankylosing spondylitis	3.3e-06	0.00179	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—TLR4—ankylosing spondylitis	3.27e-06	0.00177	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	3.2e-06	0.00174	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TNF—ankylosing spondylitis	3.13e-06	0.0017	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CRP—ankylosing spondylitis	3.04e-06	0.00165	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL1RN—ankylosing spondylitis	2.94e-06	0.0016	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—TLR4—ankylosing spondylitis	2.92e-06	0.00158	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MMP3—ankylosing spondylitis	2.79e-06	0.00151	CbGpPWpGaD
Celecoxib—PTGS2—Disease—B3GNT2—ankylosing spondylitis	2.71e-06	0.00147	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD79A—ankylosing spondylitis	2.59e-06	0.0014	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—B3GNT2—ankylosing spondylitis	2.27e-06	0.00123	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.13e-06	0.00116	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL1A—ankylosing spondylitis	2.12e-06	0.00115	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD40LG—ankylosing spondylitis	2.11e-06	0.00114	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTGER4—ankylosing spondylitis	2.04e-06	0.0011	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-B—ankylosing spondylitis	2e-06	0.00109	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-A—ankylosing spondylitis	1.86e-06	0.00101	CbGpPWpGaD
Celecoxib—ALB—Metabolism—B3GNT2—ankylosing spondylitis	1.83e-06	0.000996	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CRP—ankylosing spondylitis	1.77e-06	0.000962	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TLR4—ankylosing spondylitis	1.7e-06	0.000922	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TNF—ankylosing spondylitis	1.56e-06	0.000846	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	1.51e-06	0.000822	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	1.5e-06	0.000815	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP3—ankylosing spondylitis	1.45e-06	0.000787	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HLA-A—ankylosing spondylitis	1.1e-06	0.000595	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	9.9e-07	0.000537	CbGpPWpGaD
